Back to Oncology
Oncologyv2012Evidence-Based

Prostate Tumor Volume & Density

Calculates prostate volume using ellipsoid formula and PSA density to help distinguish between benign prostatic hyperplasia (BPH) and prostate cancer. This tool assists in biopsy decision-making, risk stratification, and treatment planning for patients with elevated PSA levels.

Clinical Input Parameters

cm
Range: 1 — 20 cm
cm
Range: 1 — 20 cm
cm
Range: 1 — 20 cm
ng/mL
Range: 0.1 — 1000 ng/mL
Clinical Assessment
Awaiting Parameters
prostate calculations
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Prostate Tumor Volume & Density is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Prostate Volume (mL) = Length × Width × Height × π/6; PSA Density (ng/mL²) = PSA (ng/mL) ÷ Prostate Volume (mL)

Clinical Pearls & Practice Notes

  • Prostate volume calculated using ellipsoid formula with π/6 correction factor
  • PSA density threshold of 0.15 ng/mL/cm³ commonly used to distinguish benign from malignant
  • Normal prostate volume is approximately 25-30 mL in adult males
  • PSA density >0.15 associated with higher probability of prostate cancer
  • Particularly useful in PSA 'gray zone' (4-10 ng/mL) for biopsy decision-making
  • Should be interpreted alongside clinical findings, DRE, and patient risk factors
  • Imaging measurements should be obtained from transrectal ultrasound (TRUS) or MRI
  • Age-related prostate enlargement should be considered in interpretation
  • May help guide active surveillance vs. treatment decisions
  • Useful for monitoring prostate size changes over time
  • Consider transition zone volume for more precise cancer risk assessment
  • Accuracy depends on precise imaging measurements and proper technique

Evidence & Literature Citations

  1. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991;145(5):984-7. doi: 10.1016/s0022-5347(17)38491-9.
  2. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147(3 Pt 2):817-21. doi: 10.1016/s0022-5347(17)37394-9.
  3. Kalish J, Cooner WH, Graham SD Jr. Serum PSA adjusted for volume of transition zone (PSATZ) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43(5):601-6. doi: 10.1016/0090-4295(94)90170-8.
  4. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050-8. doi: 10.1093/jnci/djt151.

Score Interpretation Ranges

Tier 1≤ pts

Tier 2≤ pts

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.